Vera Therapeutics Inc(VERA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 14 at 4:00 AM ET (Korea 9/14 17:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -5.87 | Insider Own | 18.87% | Shs Outstand | 72.0M | Perf Week | 0.17% |
| Market Cap | 2.53B | Forward P/E | - | EPS next Y | 29.2% | Insider Trans | -0.91% | Shs Float | 58.5M | Perf Month | 16.87% |
| Enterprise Value | 2.10B | PEG | - | EPS next Q | -1.61 | Inst Own | 98.38% | Short Float | 33.99% | Perf Quarter | 4.16% |
| Income | -0.40B | P/S | - | EPS this Y | -34.29% | Inst Trans | 8.61% | Short Ratio | 9.31 | Perf Half Y | -14.87% |
| Sales | 0.00B | P/B | 6.19 | EPS next 5Y | 53.56% | ROA | -72.32% | Short Interest | 19.87M | Perf YTD | -30.79% |
| Book/sh | 5.67 | P/C | 5.06 | EPS past 3/5Y | -11.65% -13.19% | ROE | -91.75% | 52W High | -37.47% ($56.05) | Perf Year | 42.89% |
| Cash/sh | 6.93 | P/FCF | - | Sales past 3/5Y | - | ROIC | -83.21% | 52W Low | 54.27% ($22.72) | Perf 3Y | 84.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -63.94% | Gross Margin | - | Volatility(W/M) | 4.21% 5.14% | Perf 5Y | 34.14% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.72 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.65 | EPS Q/Q | -27.01% | Profit Margin | - | RSI (14) | 53.36 | Recom | 1.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.65 | Sales Q/Q | - | SMA20 | 3.31% ($33.93) | Beta | 1.05 | Target Price | $77.36 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/8/10 | SMA50 | -0.47% ($35.22) | Rel Volume | 1.63 | Prev Close | $33.6 |
| Employees | 249 | LT Debt/Eq | 0.18 | EPS/Sales Surpr. | 3.54% - | SMA200 | -11.4% ($39.56) | Avg Volume(3M) | 2.14M | Price | $35.05 |
| IPO | 2021/5/14 | Option/Short | Yes/Yes | Trades | 20415 | Volume | 3,485,704 | Change | 4.32% |
Company
VERA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US-based clinical-stage biotech company developing therapeutics for immune-mediated kidney diseases. The company is developing treatments that target immune-related kidney disorders involving immunoglobulins, with a focus on a late-stage clinical lead candidate, advancing differentiated therapies in the kidney and immunology disease space where there is significant unmet medical need.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
VERA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -34.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +84.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 98.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SBIO 0.02%
XBI 0.01%
LABU 0.01%
BBC 0.01%
DWAS 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
TQQQ 34.7B
SOXL 19.5B
QLD 13.9B
SSO 8.8B
SPXL 6.9BIt ranks #4 in the industry
Based on market cap of $3B.
VERA $3B PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is VERA?
VERA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VERA?
The market cap of VERA is approximately $2.5B, ranking 1,920 within its sector.
What is the 52-week high and low for VERA?
VERA has recorded a 52-week high of $56.05 and a low of $22.72.
